Compare BridgeBio Pharma Inc (BBIO) vs Etsy Inc (ETSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Etsy Inc — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while Etsy Inc trades at $83.12 (market cap $7.88B). The key difference: BridgeBio Pharma Inc is far larger — about 2.1× Etsy Inc's market cap, and Etsy Inc is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | ETSY | |
|---|---|---|
Market Cap | $16.46B | $7.88B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $83.06 |
52-Week Low | $44.81 | $44.05 |
Enterprise Value | $18.02B | $9.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
ETSY trades at $80.53, down 0.64% today, with strong technical momentum as the stock has rallied 40% over the past three months. The company shows mixed fundamentals with revenue stabilizing around $2.9B but net income declining to $163M in 2025. Recent earnings beats and positive analyst sentiment (48.9% buy ratings) support the bullish technical outlook, though valuation metrics remain elevated with a P/E of 30.85.
The outlook remains cautiously optimistic with AI-driven marketplace improvements and seller tools driving growth potential. Key risks include active buyer declines, competitive pressures from larger e-commerce players, and high debt levels. The stock trades near analyst consensus targets, suggesting limited near-term upside from current levels despite positive momentum indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
